# Adaptilens

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adaptilens

- Industry: Healthcare Specialists
- Headquarters: Boston, US
- Website: www.adaptilens.com
- Total disclosed funding: $19M
- Latest round: Series A (Apr 29, 2024)
- Investors on record: 4

## About

Founded in 2019, and based in Massachusetts, US, Adaptilens, LLC operates as a developer of an intraocular lens that is injected into the patient's eyes. The company was founded by its CEO, Liane Clamen. In April 2024, Adaptilens, LLC raised USD 17.5 million in Series A, led by Perceptive Xontogeny Venture Funds, with participation from 380 Cap.

Adaptilens researches and develops accommodating intraocular lenses (A-IOL) for cataract patients that restore their eye's ability to focus at multiple distances, thus reducing the need for glasses or contact lenses. The company’s pre-clinical product will mimic the natural human lens, allowing patients to see clearly at near, far, and intermediate distances.

The company plans to use the April 2024 funding for its product growth from pre-clinical to clinical.

## Funding rounds

- Series A, Apr 29, 2024, $18M — Pillar, Accanto Partners, 380 Cap, Perceptive Xontogeny Venture Funds
- Seed, Nov 12, 2020, $1.6M — Pillar, Accanto Partners

## Investors

- Pillar (https://capitalatlas.ai/funds/pillar) — Seed, Series A
- Accanto Partners (https://capitalatlas.ai/funds/accanto-partners) — Seed, Series A
- 380 Cap (https://capitalatlas.ai/funds/380-cap) — Series A
- Perceptive Xontogeny Venture Funds — Series A